Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

Julie R. Park, Rochelle Bagatell, Wendy B. London, John M. Maris, Susan L. Cohn, Katherine M. Mattay, Michael Hogarty

Research output: Contribution to journalReview articlepeer-review

262 Scopus citations


Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.

Original languageEnglish
Pages (from-to)985-993
Number of pages9
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 2013
Externally publishedYes


  • Children
  • Malignancies
  • Neuroblastoma


Dive into the research topics of 'Children's Oncology Group's 2013 blueprint for research: Neuroblastoma'. Together they form a unique fingerprint.

Cite this